Back
Insight Molecular Diagnostics, Inc. 10K Form
Sell
43
IMDX
Insight Molecular Diagnostics, Inc.
Last Price:
$5.59
Seasonality Move:
13.47%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
10K form not available
Receive IMDX News And Ratings
See the #1 stock for the next 7 days that we like better than IMDX
IMDX Financial Statistics
Sales & Book Value
| Annual Sales: | $1.9M |
|---|---|
| Cash Flow: | $-5.6M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $-0.32 |
| Price / Book: | 196.14 |
Profitability
| EPS (TTM): | -2.83050 |
|---|---|
| Net Income (TTM): | $-60.8M |
| Gross Margin: | $-666K |
| Return on Equity: | -1008.03% |
| Return on Assets: | -116.83% |
Insight Molecular Diagnostics, Inc. Earnings Forecast
Key Insight Molecular Diagnostics, Inc. Financial Ratios
-
The Gross Profit Margin over the past 12 years for IMDX is -35.41%.
-
The Selling, General & Administrative Expenses for IMDX have been equal to 752.15% of Gross Profit Margin.
-
The Research & Development expenses have been 467.62% of Revenue.
-
The Net Earning history of IMDX is -3,225.04% of Total Revenues.
-
Per Share Earnings over the last 12 years have been positive in 3 years.
Insight Molecular Diagnostics, Inc. Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | IMDX |
| Website: | oncocyte.com |
Debt
| Debt-to-Equity Ratio: | -0.34 |
|---|---|
| Current Ratio: | 2.79 |
| Quick Ratio: | 2.57 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |
IMDX Technical Analysis vs Fundamental Analysis
Sell
43
Insight Molecular Diagnostics, Inc. (IMDX)
is a Sell
Is Insight Molecular Diagnostics, Inc. a Buy or a Sell?
-
Insight Molecular Diagnostics, Inc. stock is rated a SellThe current Insight Molecular Diagnostics, Inc. [IMDX] share price is $5.34. The Score for IMDX is 43, which is 14% below its historic median score of 50, and infers higher risk than normal.